|Bid||11.55 x 800|
|Ask||11.63 x 1200|
|Day's range||11.56 - 12.10|
|52-week range||11.50 - 32.48|
|Beta (5Y monthly)||0.91|
|PE ratio (TTM)||N/A|
|Earnings date||13 Apr 2022 - 18 Apr 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||14 Oct 1999|
|1y target est||14.00|
Although high costs and a drab view remain concerning, Rite Aid (RAD) looks well-positioned on robust demand, enhanced omni-channel capabilities and strength in PBM.
At-home testing options are limited in availability, delayed in delivery time, or entirely out of stock depending on the brand and retailer as the Omicron variant surges in the U.S.
Increased demand for COVID-19 vaccination and testing, and growth in the Retail Pharmacy unit aid Rite Aid's (RAD) Q3 results.